eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | hepatitis c |
| Symptom | C0011570|depression |
| Sentences | 30 |
| PubMedID- 21615916 | For instance, ido activity (measured indirectly by the kyn/trp ratio) and an increased neurotoxic potential predict the occurrence of depression in patients with hepatitis c being treated with ifn-α based immunotherapy . |
| PubMedID- 24778869 | Although the interaction between fatigue and depression in patients with chronic hepatitis c infection (hcv) has been recognized, the biological correlates of this observation have yet to be reported. |
| PubMedID- 24934987 | depression was not associated with hepatitis c (hcv-infected 29%, non-infected 35%; p = 0.25). |
| PubMedID- 25359924 | Sadness and mild cognitive impairment as predictors for interferon-alpha-induced depression in patients with hepatitis c. |
| PubMedID- 24742598 | depression and neuroticism in patients with chronic hepatitis c: correlation with peripheral blood mononuclear cells activation. |
| PubMedID- 24608038 | Asymmetric dimethylarginine responses during interferon-alpha-induced depression in patients with chronic hepatitis c infection. |
| PubMedID- 23942342 | A biopsychosocial model of interferon-alpha-induced depression in patients with chronic hepatitis c infection. |
| PubMedID- 24918850 | Interferon-induced depression in patients with hepatitis c: an epidemiologic study. |
| PubMedID- 25670957 | Bupropion for interferon-alpha-induced depression in patients with hepatitis c viral infection: an open-label study. |
| PubMedID- 24608155 | Interferon-alpha induced depression in a patient with hepatitis c. |
| PubMedID- 21654873 | We suggest that interactions between psychobehavioral, genetic, and biological risk factors are of particular importance in the occurrence of depression in patients with hepatitis c taking interferon-alpha. |
| PubMedID- 24644496 | This may be due to less therapeutic options, more social fear and non-significant prognosis of chronic hepatitis c that lead to more depression rate (14, 15). |
| PubMedID- 20587769 | Novel treatment strategies for depression in patients with hepatitis c. |
| PubMedID- 23648373 | Specific serotonin reuptake inhibitors prevent interferon-alpha-induced depression in patients with hepatitis c: a meta-analysis. |
| PubMedID- 24012293 | Conclusion: antidepressant pretreatment with selective serotonin reuptake inhibitors lowers the incidence and severity of ifn-associated depression in patients with chronic hepatitis c infection or malignant melanoma. |
| PubMedID- 21691274 | Association of a polymorphism in the indoleamine- 2,3-dioxygenase gene and interferon-alpha-induced depression in patients with chronic hepatitis c. |
| PubMedID- 22075738 | Objective: to prospectively evaluate depressive symptoms and risk factors for depression in patients with chronic hepatitis c (chc) treated with pegylated interferon alpha therapy combined with oral ribavirin (peg-ifn-alpha+rbv) and to analyze self-rating scale for depression in comparison to observer-based scale in the given population. |
| PubMedID- 24955454 | Conclusions: a history of depression is common with hepatitis c but does not affect initiation of antiviral treatment, despite substantially increased risk of psychiatric side-effects. |
| PubMedID- 24372654 | Objective: to conduct a systematic review and meta-analysis evaluating the efficacy and safety of antidepressant medications for the prevention of interferon-alpha (inf-alpha)-associated depression in patients with chronic hepatitis c virus (hcv). |
| PubMedID- 22070000 | Objective: the aim of the study was to identify the presence of depression in patients with chronic hepatitis c, predicting factors for its expression, and the impact of depression on the quality of life in these patients. |
| PubMedID- 24204676 | Can antidepressants prevent pegylated interferon-alpha/ribavirin-associated depression in patients with chronic hepatitis c: meta-analysis of randomized, double-blind, placebo-controlled trials. |
| PubMedID- 25868672 | We prospectively evaluate depressive symptoms and risk factors for major depression in patients with hepatitis c virus treated with antiviral combined therapy. |
| PubMedID- 21423320 | Not only is the prevalence of depression in patients with hepatitis c higher than the general population, antiviral therapy increases the likelihood of a variety of neuropsychiatric complications, including worsening depression, anxiety, and suicidal ideation . |
| PubMedID- 23108508 | The role of attachment style and depression in patients with hepatitis c. |
| PubMedID- 22326842 | depression and anxiety in patients with hepatitis c virus (hcv) infection influence their health-related quality of life and their adherence to antiviral treatment. |
| PubMedID- 24839091 | Serotonin-norepinephrine reuptake inhibitor desvenlafaxine for the treatment of interferon alfa-associated depression in patients with hepatitis c. |
| PubMedID- 20569656 | The prevalence of depression is increased in patients with chronic hepatitis c virus (hcv) infection. |
| PubMedID- 23139898 | Gene expression profiles associated with depression in patients with chronic hepatitis c (ch-c). |
| PubMedID- 21762832 | Screening for depression in patients with hepatitis c using the beck depression inventory-ii: do somatic symptoms compromise validity. |
| PubMedID- 25116763 | Incidence of depression in patients with chronic hepatitis c receiving combination therapy of pegylated interferon-alpha and ribavirin. |
Page: 1